caption text
In his 15 years as a lung cancer specialist, Professor Nicolas Girard, MD, PhD, of the Curie-Montsouris Thorax Institute has seen – and helped advance – dramatic changes in how patients with this disease are treated. Yet despite this progress, lung cancer remains the leading cause of cancer deaths globally, and even patients who are diagnosed early often experience recurrence.
“Patients with lung cancer who are eligible for resection undergo surgical treatment with a curative intent, meaning the aim is to avoid any event related to cancer after surgery,” said Professor Girard. “Unfortunately, given the aggressiveness of the disease, many patients eventually experience recurrence.”
Some patients receive chemotherapy before or after surgery with the goal of reducing the likelihood of the cancer’s return, but the evidence to support this treatment approach remains limited. To better protect patients with lung cancer against disease recurrence, additional treatment options are needed urgently.
